TRAUMEEL® PRODUCT MONOGRAPH42

Study design Patients with various musculoskeletal injuries being treated by German

physicians received: Traumeel® as monotherapy or in combination with homeopathic products

n=69: 39 male, 30 female; mean age 32.6 years; 67 acute injury, 2 chronic; additional measures taken in 20; co-medication taken by 4.

conventional medicines n=64: 31 male, 33 female; mean age 31.6 years; 61 acute, 3 chronic injury; additional measures taken in 26; co-medication taken by 4.

Additional measures (e.g. functional treatment, compression) and the use of co- medication were permitted and recorded.

Traumeel® was used in more than one application form by 33% of Traumeel® group.

Conventional medicines were: analgesics/anti-rheumatics 52%, anticoagulants 16%, anti-inflammatory 7% and miscellaneous 25%; monotherapy in 69% and combination therapy in 31% of patients.

Outcome measures Primary: rate of resolution of the principal and secondary symptoms at the end of

therapy. Secondary: time until symptomatic improvement and treatment outcome as

assessed by the physician.

NON-RANDOMIZED OBSERVATIONAL STUDIES

Traumeel® compared with conventional therapy in the treatment of injuries

Schneider C, Schneider B, Hanisch J, van Haselen R. The role of a homeopathic preparation compared with conventional therapy in the treatment of injuries: an observational cohort study. Complement Ther Med. 2008,16(1):22 27.

STUDY DESIGN FORMULATION INDICATION(S) Multi-center, prospective, comparative observational cohort study.

Traumeel® in various forms, e.g. tablets, ointment and injections.

Various musculoskeletal injuries.